Survival of health workers infected by SARS-CoV-2 in the context of vaccination against COVID-19 in Peru

Escobar-Agreda, Stefan; Silva-Valencia, Javier; Rojas-Mezarina, Leonardo; Vargas-Herrera, Javier

doi:10.1101/2021.08.03.21260614

Cited by 4 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the trend in deaths decreased after vaccination; while, in the general population, the trend was to increase until reaching the highest value of the pandemic during the second wave. This confirms the results of Escobar-Agreda 35 who found a higher survival rate in Peruvian healthcare workers in 2021 after the start of vaccination. This would show the effectiveness of vaccination since without it, the number of deaths from COVID-19 would have increased notably in a similar way to what happened with the general Peruvian population.…”

Section: Discussionsupporting

confidence: 91%

“…The greatest risk of probable reinfection was found in those who worked in public establishments of the MINSA/GORE, PNP/FFAA, as well as in those who worked outside the capital, particularly in establishments in the Amazon and the Andean region; a higher risk was also documented in those who had direct contact with COVID-19 cases in their workplace. It is possible that the greater limitations existing in the establishments of the MINSA/GORE, PNP/FAA and outside the capital of Peru, have contributed to the reinfection of healthcare workers during the pandemic's greatest activity, moments in which there have been documented deficit of personal protective equipment, as well as a greater exposure to COVID-19 due to the overwhelming patient demand 17,35,[39][40][41] .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hospitalization, death, and probable reinfection in Peruvian healthcare workers infected with SARS-CoV-2: a national retrospective cohort study

Ramos

Guerrero

Napanga-Saldaña

et al. 2022

Preprint

View full text Add to dashboard Cite

OBJECTIVE: To determine if the occupation is a risk factor for probable reinfection, hospitalization, and death from COVID 19 in Peruvian healthcare workers infected with SARS CoV2. MATERIAL AND METHODS: Retrospective cohort study. Healthcare workers who presented SARS CoV 2 infection between March 1, 2020, and August 9, 2021, were included. Occupational cohorts were reconstructed from the following sources of information: the National Epidemiological Surveillance System, molecular tests (NETLAB), results of serology and antigen tests (SICOVID 19), National Registry of Health Personnel (INFORHUS), and National Information System of Deaths (SINADEF). The incidence of probable reinfection, hospitalization, and death from COVID 19 was obtained in the cohorts of health auxiliaries and technicians, nursing staff, obstetricians, physicians, and other healthcare workers. Using a log-binomial generalized linear model, we evaluated whether the occupation was a risk factor for probable reinfection, hospitalization, and death from COVID 19, obtaining the adjusted relative risk (RR AJ). RESULTS: 90,672 healthcare workers were included. 8.1% required hospitalization, 1.7% died from COVID 19, and 2.0% had probable reinfection. A similar incidence of probable reinfection was found in the 5 cohorts (1.9% to 2.2%). Physicians had a higher incidence of hospitalization (13.2%) and death (2.6%); however, they were also those who presented greater susceptibility linked to non-occupational variables such as age and comorbidities. The multivariate analysis found that physicians (RR=1.691; CI 95: 1.556 to 1.837) had a higher risk of hospitalization and that the occupation of health technician and the assistant was the only one that constituted a risk factor for mortality from COVID-19 (RR =1.240; 95% CI: 1.052 to 1.463). CONCLUSIONS: Peruvian health technicians and auxiliaries have a higher risk of death from COVID-19 linked to their occupation, while doctors have higher mortality due to non-occupational factors. Physicians had a higher risk of hospitalization independent of the presence of comorbidities and age; likewise, all occupations had a similar risk of probable reinfection.

show abstract

Section: Discussionsupporting

confidence: 91%

mentioning

confidence: 99%

Hospitalization, death, and probable reinfection in Peruvian healthcare workers infected with SARS-CoV-2: a national retrospective cohort study

Ramos

Guerrero

Napanga-Saldaña

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In Argentina, two-dose vaccine effectiveness (VE) against COVID-19 related mortality was 84% among those aged ≥60 years [11] . In a large cohort of health care workers in Peru, two-dose VE was 50% against infection and 94% against COVID-19-related mortality [12] . In a nation-wide observational study in Hungary with 895,000 adult BIBP-CorV recipients, two-dose VE was 69% against infection and 88% against COVID-19 related mortality [13] .…”

Section: Discussionmentioning

confidence: 99%

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco

Zhang¹,

Belayachi

Yang³

et al. 2022

Preprint

View full text Add to dashboard Cite

The Kingdom of Morocco approved BBIBP-CorV (Sinopharm) COVID-19 vaccine for emergency use on 22 January 2021 in a two-dose, three-to-four-week interval schedule. We conducted a case-control study to determine real-world BBIBP-CorV vaccine effectiveness (VE) against serious or critical hospitalization of individuals RT-PCR-positive for SARS-CoV-2 during the first five months of BBIBP-CorV use in Morocco.The study was conducted among adults 18-99 years old who were tested by RT-PCR for SARS-CoV-2 infection between 1 February and 30 June 2021. RT-PCR results were individually linked with outcomes from the COVID-19 severe or critical hospitalization dataset and with vaccination histories from the national vaccination registration system. Individuals with partial vaccination (<2 weeks after dose two) or in receipt of any other COVID-19 vaccine were excluded. Unadjusted and adjusted VE estimates against hospitalization for serious or critical illness were made by comparing two-dose vaccinated and unvaccinated individuals in logistic regression models, calculated as (1-odds ratio) * 100%.There were 348,190 individuals able to be matched across the three databases. Among these, 140,892 were fully vaccinated, 206,149 were unvaccinated, and 1,149 received homologous BBIBP-CorV booster doses. Unadjusted, full-series, unboosted BBIBP-CorV VE against hospitalization for serious or critical illness was 90.2% (95%CI: 87.8% - 92.0%). Full-series, unboosted VE, adjusted for age, sex, and calendar day of RT-PCR test, was 88.5% (95%CI: 85.8% - 90.7%). Calendar day- and sex-adjusted VE ranged from 93.9% to 100% for individuals <60 years, and was 53.3% for individuals 60 years and older. There were no serious or critical illnesses among BBIBP-CorV-boosted individuals.Effectiveness of Sinopharm’s BBIBP-CorV was consistent with phase III clinical trial results. Two doses of BBIBP-CorV was highly protective against COVID-19-associated serious or critical hospitalization in working-age adults under real-world conditions and moderately effective in older adults. Booster dose VE should be evaluated, as booster doses of BBIBP-CorV are recommended and are being used.

show abstract

“…Peru implemented the SARS-CoV-2 vaccination in February 2021, initially including immunization of health workers, the population with comorbidities, and subsequently, the overall population. The vaccination led to a reduction in the COVID-19 mortality rate in the Peruvian population [ 15 , 16 ]. In this setting, our findings can help to explain the indirect impact of the SARS-CoV-2 vaccination on the COVID-19 mortality risk reduction in regions where the prevalence of obesity is high.…”

Section: Discussionmentioning

confidence: 99%

“…To control the COVID-19 pandemic and mitigate mortality associated with its complications, Peru launched the COVID-19 vaccination on 9 February 2021, which initially included immunization of health workers and subsequently encompassed the overall population [ 14 ]. During the post-vaccination months, there has been a reduction in the COVID-19 mortality rate in the Peruvian population [ 15 , 16 ]. In this setting, we assessed the association between incidence, mortality, and case fatality rate due to COVID-19 and the prevalence rates of hypertension, obesity, overweight, tobacco, and alcohol use in the Peruvian population aged >15 years during the first and second year (since the launch of the COVID-19 vaccination) of the COVID-19 pandemic.…”

Section: Introductionmentioning

confidence: 99%

COVID-19, Non-Communicable Diseases, and Behavioral Factors in the Peruvian Population ≥ 15 Years: An Ecological Study during the First and Second Year of the COVID-19 Pandemic

Canorio

Sánchez

Ramírez-Soto

2022

IJERPH

View full text Add to dashboard Cite

A range of health-related and behavioral risk factors are associated with COVID-19 incidence and mortality. In the present study, we assess the association between incidence, mortality, and case fatality rate due to COVID-19 and the prevalence of hypertension, obesity, overweight, tobacco and alcohol use in the Peruvian population aged ≥15 years during the first and second year of the COVID-19 pandemic. In this ecological study, we used the prevalence rates of hypertension, overweight, obesity, tobacco, and alcohol use obtained from the Encuesta Demográfica y de Salud Familiar (ENDES) 2020 and 2021. We estimated the crude incidence and mortality rates (per 100,000 habitants) and case fatality rate (%) of COVID-19 in 25 Peruvian regions using data from the Peruvian Ministry of Health that were accurate as of 31 December 2021. Spearman correlation and lineal regression analysis was applied to assess the correlations between the study variables as well as multivariable regression analysis adjusted by confounding factors affecting the incidence and mortality rate and case fatality rate of COVID-19. In 2020, adjusted by confounding factors, the prevalence rate of obesity (β = 0.582; p = 0.037) was found to be associated with the COVID-19 mortality rate (per 100,000 habitants). There was also an association between obesity and the COVID-19 case fatality rate (β = 0.993; p = 0.014). In 2021, the prevalence of obesity was also found to be associated with the COVID-19 mortality rate (β = 0.713; p = 0.028); however, adjusted by confounding factors, including COVID-19 vaccination coverage rates, no association was found between the obesity prevalence and the COVID-19 mortality rate (β = 0.031; p = 0.895). In summary, Peruvian regions with higher obesity prevalence rates had higher COVID-19 mortality and case fatality rates during the first year of the COVID-19 pandemic. However, adjusted by the COVID-19 vaccination coverage, no association between the obesity prevalence rate and the COVID-19 mortality rate was found during the second year of the COVID-19 pandemic.

show abstract

Survival of health workers infected by SARS-CoV-2 in the context of vaccination against COVID-19 in Peru

Cited by 4 publications

References 9 publications

Hospitalization, death, and probable reinfection in Peruvian healthcare workers infected with SARS-CoV-2: a national retrospective cohort study

Hospitalization, death, and probable reinfection in Peruvian healthcare workers infected with SARS-CoV-2: a national retrospective cohort study

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco

COVID-19, Non-Communicable Diseases, and Behavioral Factors in the Peruvian Population ≥ 15 Years: An Ecological Study during the First and Second Year of the COVID-19 Pandemic

Contact Info

Product

Resources

About